Alnylam Pharmaceuticals Inc (ALNY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Alnylam Pharmaceuticals Inc (ALNY) has a cash flow conversion efficiency ratio of 0.207x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($163.56 Million) by net assets ($789.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Alnylam Pharmaceuticals Inc worth for the company's overall valuation and market capitalisation.
Alnylam Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2002–2025)
This chart illustrates how Alnylam Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View ALNY stock price and chart for real-time trading data and today's change.
Alnylam Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alnylam Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Review ALNY FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ADYEN NV UNSP.ADR/001
F:1N8U
|
N/A |
|
HANN.RUECKV.SE ADR 1/2/ON
F:HNRB
|
0.128x |
|
Intact Financial Corporation
TO:IFC
|
0.050x |
|
Banco Bradesco S.A
F:BREC
|
-0.288x |
|
JSW Steel Limited
NSE:JSWSTEEL
|
0.114x |
|
Sunbelt Rentals Holdings, Inc.
NYSE:SUNB
|
0.128x |
|
Northern Trust Corporation
NASDAQ:NTRS
|
-0.005x |
|
Atlas Copco AB Series B
ST:ATCO-B
|
0.047x |
Annual Cash Flow Conversion Efficiency for Alnylam Pharmaceuticals Inc (2002–2025)
The table below shows the annual cash flow conversion efficiency of Alnylam Pharmaceuticals Inc from 2002 to 2025. Also see ALNY asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $789.18 Million | $524.08 Million | 0.664x | +636.00% |
| 2024-12-31 | $67.09 Million | $-8.31 Million | -0.124x | +73.75% |
| 2023-12-31 | $-220.64 Million | $104.16 Million | -0.472x | -113.80% |
| 2022-12-31 | $-158.22 Million | $-541.27 Million | 3.421x | +413.58% |
| 2021-12-31 | $588.20 Million | $-641.69 Million | -1.091x | -80.28% |
| 2020-12-31 | $1.02 Billion | $-614.96 Million | -0.605x | -212.68% |
| 2019-12-31 | $1.44 Billion | $-278.43 Million | -0.194x | +55.22% |
| 2018-12-31 | $1.30 Billion | $-562.62 Million | -0.432x | -99.41% |
| 2017-12-31 | $1.77 Billion | $-382.79 Million | -0.217x | +35.19% |
| 2016-12-31 | $920.22 Million | $-307.70 Million | -0.334x | -123.59% |
| 2015-12-31 | $1.26 Billion | $-189.14 Million | -0.150x | +15.47% |
| 2014-12-31 | $936.27 Million | $-165.64 Million | -0.177x | +30.34% |
| 2013-12-31 | $270.35 Million | $-68.66 Million | -0.254x | +70.55% |
| 2012-12-31 | $134.05 Million | $-115.61 Million | -0.862x | -16.88% |
| 2011-12-31 | $118.00 Million | $-87.07 Million | -0.738x | -38.44% |
| 2010-12-31 | $158.23 Million | $-84.34 Million | -0.533x | -31.48% |
| 2009-12-31 | $177.97 Million | $-72.14 Million | -0.405x | -225.12% |
| 2008-12-31 | $202.12 Million | $65.49 Million | 0.324x | -67.16% |
| 2007-12-31 | $199.17 Million | $196.52 Million | 0.987x | +905.92% |
| 2006-12-31 | $201.17 Million | $-24.63 Million | -0.122x | +54.12% |
| 2005-12-31 | $61.78 Million | $-16.48 Million | -0.267x | +37.09% |
| 2004-12-31 | $46.14 Million | $-19.57 Million | -0.424x | -188.30% |
| 2003-12-31 | $-26.71 Million | $-12.83 Million | 0.480x | +74.62% |
| 2002-12-31 | $-4.65 Million | $-1.28 Million | 0.275x | -- |
About Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute h… Read more